KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Gsk (GSK) over the last 17 years, with Q2 2025 value amounting to -$11.34.

  • Gsk's Debt to Equity changed N/A to -$11.34 in Q2 2025 from the same period last year, while for Jun 2025 it was -$11.34, marking a year-over-year change of. This contributed to the annual value of -$0.94 for FY2024, which is 16955.87% down from last year.
  • According to the latest figures from Q2 2025, Gsk's Debt to Equity is -$11.34.
  • Over the past 5 years, Gsk's Debt to Equity peaked at $1.98 during Q4 2022, and registered a low of -$17.12 during Q1 2021.
  • Its 5-year average for Debt to Equity is -$3.67, with a median of -$0.94 in 2024.
  • In the last 5 years, Gsk's Debt to Equity soared by 2318.96% in 2022 and then plummeted by 16955.87% in 2024.
  • Gsk's Debt to Equity (Quarter) stood at $1.61 in 2021, then rose by 23.19% to $1.98 in 2022, then crashed by 31.83% to $1.35 in 2023, then tumbled by 169.56% to -$0.94 in 2024, then crashed by 1108.14% to -$11.34 in 2025.
  • Its Debt to Equity stands at -$11.34 for Q2 2025, versus -$0.94 for Q4 2024 and $1.35 for Q4 2023.